MedPath

Cotrimoxazole in hospitalised patients with severe COVID-19 infectio

Not Applicable
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Registration Number
CTRI/2021/02/031012
Lead Sponsor
Dept of Health and Family Welfare Government of West Bengal
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

a. Adult individuals, age >18 and <65 years

b. COVID-19 infection documented by a positive RT-PCR test

c. Hospitalised patients with severe COVID-19 infection, characterized by

fever (at the time of screening or when admitted) and requiring supplemental oxygen through non- re-breath mask between 10L-15L/ min.

d. Clinical/radiological evidence of interstitial pneumonia requiring admission (optional)

e. Informed verbal consent under urgent conditions, documented in the electronically

Exclusion Criteria

a. Patients who require invasive or non-invasive (including CPAP and high flow nasal cannula) ventilation at the time of inclusion.

b. AST/ALT values >5 fold the ULN.

c. Documented impairment of renal function

d. Absolute neutrophil count below 500 cells/mm3

e. Absolute platelet count below 50,000 cells/mm3

f. Documented sepsis or high suspicion of superimposed severe bacterial or fungal infection

g. Comorbidities or concomitant medications likely to be incompatible for cotrimoxazole use

h. Pregnancy or lactation.

i. History of cotrimoxazole hypersensitivity

j. Patients participating in another clinical trial for SARS-CoV-2 infection

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation compared to baseline (Score ranges 1-7)Timepoint: Baseline <br/ ><br>Day 7
Secondary Outcome Measures
NameTimeMethod
1.Changes in body temperature, respiratory rate, CRP, SpO2 <br/ ><br>2.Incidence of serious and non-serious adverse events <br/ ><br>Timepoint: Baseline <br/ ><br>Day 7
© Copyright 2025. All Rights Reserved by MedPath